Bfl-1, also known as Bcl-2-related protein A1 (Bcl-2A1), is an anti-apoptotic member of the Bcl-2 family of proteins.1 It is composed of two Bcl-2 homology (BH) domains (BH1 and BH2), which facilitate binding to Bim, Bid, PUMA, and Noxa, putative BH3 and BH4 domains, and a C-terminal region that regulates localization and function.1,2 Bfl-1 expression can be induced by cytokines such as IL-1β and TNF-α and is primarily expressed in leukocytes, the spleen, and the lungs but is also expressed in the small intestine, testis, and thymus and localizes to the mitochondria.3,4 However, a short splice variant, Bfl-1S, localizes to the nucleus.5 Bfl-1 is involved in p53-dependent apoptosis and autophagy.2,6 Ectopic overexpression of BCL2A1 induces resistance to the Bcl-2 inhibitor venetoclax (ABT-199; Item No. 16233) in cancer cells, and Bfl-1 is overexpressed in several cancers.7,8 Cayman’s Bfl-1 (human, recombinant) protein consists of 170 amino acids and has a calculated molecular weight of 19.7 kDa.WARNING This product is not for human or veterinary use.